BioLife Solutions (BLFS) Stock Price, News & Analysis

Company Overview

BioLife Solutions (NASDAQ:BLFS) is a leading developer and manufacturer of biopreservation media and automated thawing instruments designed to support the cell and gene therapy, regenerative medicine, and biobanking markets. The company’s products are engineered to protect living cells during storage, transportation, and preparation for clinical or research applications. Its core offerings include proprietary cryopreservation formulations—such as CryoStor® and HypoThermosol®—and ThawSTAR® automated thawing systems, which help standardize and streamline critical bioprocessing steps.

Founded in 1995 and headquartered in Bothell, Washington, BioLife Solutions has grown from a small startup into a global supplier serving pharmaceutical manufacturers, academic research centers, contract development and manufacturing organizations, and cell therapy developers. The company operates manufacturing facilities in North America and Europe, and it has established a network of distributors and partnerships that extend its reach to Asia Pacific and other key biotech hubs. These regional operations are backed by quality systems compliant with FDA and EMA regulations.

Over its history, BioLife Solutions has built a robust intellectual property portfolio covering biopreservation media compositions and thawing technologies. The company collaborates closely with industry leaders to validate its products in a range of cell therapy platforms, including CAR-T, NK cell, gene-edited stem cell, and tissue regeneration therapies. BioLife’s solutions are integrated into both preclinical research workflows and late-stage clinical and commercial manufacturing processes.

Under the leadership of President and CEO James Miceli, BioLife Solutions continues to invest in research and development to enhance product performance and expand its offering of single-use systems and on-demand services. With a focus on quality, regulatory support, and customer training, the company aims to drive consistency and efficiency in biopreservation workflows, helping clients advance critical therapies from the lab bench to the patient.

Key Stats

• Today's Range: $22.48 to $23.34
• 50-Day Range: $20.69 to $25.27
• 52-Week Range: $18.70 to $29.55
• Volume: 503,412 shs
• Average Volume: 420,684 shs
• Market Capitalization: $1.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.17
• Consensus Rating: Buy

BioLife Solutions Stock Analysis - MarketRank™

BioLife Solutions scored higher than 62% of companies evaluated by MarketBeat, and ranked 372nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioLife Solutions has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioLife Solutions are expected to grow in the coming year, from ($0.30) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLife Solutions is -80.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLife Solutions is -80.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLife Solutions has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.39% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLife Solutions does not currently pay a dividend.

Dividend Growth

BioLife Solutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.39% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.69

News Sentiment

BioLife Solutions has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioLife Solutions this week, compared to 5 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,965,366.00 in company stock.

Percentage Held by Insiders

Only 2.20% of the stock of BioLife Solutions is held by insiders.

Percentage Held by Institutions

93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BLFS Stock Analysis - Frequently Asked Questions

How have BLFS shares performed this year?

BioLife Solutions' stock was trading at $25.96 at the start of the year. Since then, BLFS shares have decreased by 10.4% and is now trading at $23.26.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its earnings results on Thursday, May, 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The medical equipment provider had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative trailing twelve-month return on equity of 0.66%.
Read the conference call transcript.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BLFS
• CIK: 834365
• Web: www.biolifesolutions.com
• Phone: (425) 402-1400
• Fax: 425-402-1433
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.17
• High Stock Price Target: $33.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +34.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.18 million
• Net Margins: -11.81%
• Pretax Margin: -8.22%
• Return on Equity: -0.66%
• Return on Assets: -0.58%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 4.73
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $82.25 million
• Price / Sales: 13.43
• Cash Flow: $0.12 per share
• Price / Cash Flow: 186.43
• Book Value: $7.52 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 47,500,000
• Free Float: 46,455,000
• Market Cap: $1.10 billion
• Optionable: Optionable
• Beta: 1.79